Personal Finance

Why ImmunoGen Shot Up 13% Today

Man extending a bull figurine with a bear figurine in background

What happened

Shares of ImmunoGen (NASDAQ: IMGN) jumped 13% on Wednesday on no obvious news, as the biotech remains a play toy for day traders.

So what

ImmunoGen is sitting in limbo right now awaiting data from its phase 3 study, dubbed Forward I, which is testing its lead drug mirvetuximab as a monotherapy in patients with ovarian cancer. With the trial fully enrolled , management expects data from the study in the first half of next year, setting up a potential approval in late 2019 or early 2020.

Valuing a biotech with an upcoming binary event is squishy -- for lack of a better word -- because there are a lot of variables that have to be estimated, including the likelihood of a positive outcome and the price-to-sales multiple investors will eventually assign the company once the drug is on the market. That lack of clarity can result in a wide trading range for the stock price, allowing day traders to jump in and out as momentum changes.

Man extending a bull figurine with a bear figurine in background

Image source: Getty Images.

Now what

Long-term investors can ignore the daily gyrations and focus on the fundamentals, which aren't likely to change until the upcoming data release. Management has indicated that it's started initial planning for a launch, but hasn't invested much, which seems like a prudent move given ImmunoGen's limited resources.

Investors also should be watching the company's earlier-stage pipeline drugs, IMGN 779 and IMGN 632, which treat acute myeloid leukemia, as well as an ongoing study called Forward II that's testing combination treatments with mirvetuximab. If Forward I fails, it'll be a big blow to ImmunoGen, but at least the biotech has a backup plan.

10 stocks we like better than ImmunoGen

When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and ImmunoGen wasn't one of them! That's right -- they think these 10 stocks are even better buys.

Click here to learn about these picks!

*Stock Advisor returns as of November 14, 2018

Brian Orelli has no position in any of the stocks mentioned. The Motley Fool recommends ImmunoGen. The Motley Fool has a disclosure policy .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

IMGN

Other Topics

Stocks

Latest Personal Finance Videos

    #TradeTalks: A Holistic Financial Picture to Give a True Indicator of your Financial Health

    Harvest Founder Nami Baral joins Jill Malandrino on Nasdaq #TradeTalks to discuss the Harvest PRO Index, holistic financial picture to give a true indicator of your financial health, not just a credit score.

    Oct 9, 2020

    The Motley Fool

    Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

    Learn More